Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes

Clinical Immunology

Volumn 139, Issue 3, 2011, Pages 350-359

  Bouchliou, Irene ^a   Miltiades, Paraskevi ^a   Nakou, Evangelia ^a   Spanoudakis, Emmanouil ^a   Goutzouvelidis, Aggelos ^a   Vakalopoulou, Sofia ^b   Garypidou, Vasilia ^b   Kotoula, Vasiliki ^a   Bourikas, George ^a   Tsatalas, Costas ^a   Kotsianidis, Ioannis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Myelodysplastic syndromes; Th17 cells; Tregs; Tumor immunity

Indexed keywords

INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CELL EXPANSION; CELL INTERACTION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL;

AGED; AGED, 80 AND OVER; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 79955949689     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.03.001     Document Type: Article

References (48)

1. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
2. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 2005, 6:338-344.
3. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804-811.
4. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.
5. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
6. Curti A., Pandolfi S., Valzasina B., Aluigi M., Isidori A., Ferri E., Salvestrini V., Bonanno G., Rutella S., Durelli I., Horenstein A.L., Fiore F., Massaia M., Colombo M.P., Baccarani M., Lemoli R.M. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007, 109:2871-2877.
7. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., Zhang Q., Lonning S., Teicher B.A., Lee C. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 2007, 178:2883-2892.
8. Qin F.X. Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. Cell. Mol. Immunol. 2009, 6:3-13.
9. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N. Engl. J. Med. 2009, 361:1872-1885.
10. Kotsianidis I., Bouchliou I., Nakou E., Spanoudakis E., Margaritis D., Christophoridou A.V., Anastasiades A., Tsigalou C., Bourikas G., Karadimitris A., Tsatalas C. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS). Leukemia 2009, 23:510-518.
11. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., Lombardi G., Wlodarski M.W., Maciejewski J.P., Farzaneh F., Mufti G.J. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
12. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. Type 17T helper cells-origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. 2009, 5:325-331.
13. Pene J., Chevalier S., Preisser L., Venereau E., Guilleux M.H., Ghannam S., Moles J.P., Danger Y., Ravon E., Lesaux S., Yssel H., Gascan H. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J. Immunol. 2008, 180:7423-7430.
14. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C.H., de Waal Malefyt R., Steinman L., Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
15. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., Novitskaya I., Khatcherian A., Bluth M.J., Lowes M.A., Krueger J.G. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 2007, 204:3183-3194.
16. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 2006, 116:1310-1316.
17. Murugaiyan G., Saha B. Protumor vs antitumor functions of IL-17. J. Immunol. 2009, 183:4169-4175.
18. Muranski P., Restifo N.P. Does IL-17 promote tumor growth?. Blood 2009, 114:231-232.
19. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 2009, 21:274-280.
20. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
21. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., Valmori D. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8635-8640.
22. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., Bover L., Hanabuchi S., Khalili J., Marinova E., Zheng B., Littman D.R., Liu Y.J. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4793-4798.
23. Kordasti S.Y., Afzali B., Lim Z., Ingram W., Hayden J., Barber L., Matthews K., Chelliah R., Guinn B., Lombardi G., Farzaneh F., Mufti G.J. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br. J. Haematol. 2009, 145:64-72.
24. Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., Classen S., Schultze J.L. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006, 107:3940-3949.
25. Su X., Ye J., Hsueh E.C., Zhang Y., Hoft D.F., Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 2010, 184:1630-1641.
26. Kryczek I., Wei S., Zou L., Altuwaijri S., Szeliga W., Kolls J., Chang A., Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 2007, 178:6730-6733.
27. Beriou G., Costantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., Hafler D.A. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009, 113:4240-4249.
28. Donnenberg A.D., Donnenberg V.S. Rare-event analysis in flow cytometry. Clin. Lab. Med. 2007, 27:627-652. (viii).
29. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., Biota C., Doffin A.C., Durand I., Olive D., Perez S., Pasqual N., Faure C., Ray-Coquard I., Puisieux A., Caux C., Blay J.Y., Menetrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 69:2000-2009.
30. Kryczek I., Liu R., Wang G., Wu K., Shu X., Szeliga W., Vatan L., Finlayson E., Huang E., Simeone D., Redman B., Welling T.H., Chang A., Zou W. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009, 69:3995-4000.
31. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
32. Kortylewski M., Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 2008, 20:228-233.
33. Langowski J.L., Zhang X., Wu L., Mattson J.D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R.A., Oft M. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
34. Muranski P., Boni A., Antony P.A., Cassard L., Irvine K.R., Kaiser A., Paulos C.M., Palmer D.C., Touloukian C.E., Ptak K., Gattinoni L., Wrzesinski C., Hinrichs C.S., Kerstann K.W., Feigenbaum L., Chan C.C., Restifo N.P. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
35. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
36. Benchetrit F., Ciree A., Vives V., Warnier G., Gey A., Sautes-Fridman C., Fossiez F., Haicheur N., Fridman W.H., Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99:2114-2121.
37. Valmori D., Raffin C., Raimbaud I., Ayyoub M. Human RORgammat+TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19402-19407.
38. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., Sacks D.L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002, 420:502-507.
39. Guyot-Revol V., Innes J.A., Hackforth S., Hinks T., Lalvani A. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 2006, 173:803-810.
40. Li S., Gowans E.J., Chougnet C., Plebanski M., Dittmer U. Natural regulatory T cells and persistent viral infection. J. Virol. 2008, 82:21-30.
41. O'Connor W., Zenewicz L.A., Flavell R.A. The dual nature of T(H)17 cells: shifting the focus to function. Nat. Immunol. 2010, 11:471-476.
42. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
43. Prabhala R.H., Pelluru D., Fulciniti M., Prabhala H.K., Nanjappa P., Song W., Pai C., Amin S., Tai Y.T., Richardson P.G., Ghobrial I.M., Treon S.P., Daley J.F., Anderson K.C., Kutok J.L., Munshi N.C. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115:5385-5392.
44. H. Nishikawa, S. Sakaguchi, Regulatory T cells in tumor immunity. Int. J. Cancer 127 (2010) 759-767.
45. Nizar S., Copier J., Meyer B., Bodman-Smith M., Galustian C., Kumar D., Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy?. Br. J. Cancer 2009, 100:1697-1703.
46. Maniati E., Soper R., Hagemann T. Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 2010, 29:5653-5662.
47. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
48. Viaud S., Flament C., Zoubir M., Pautier P., Lecesne A., Ribrag V., Soria J.C., Marty V., Vielh P., Robert C., Chaput N., Zitvogel L. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011, 71:661-665.